SAS - Enhancing Success Rates with Adaptive Clinical Trials
GLP-1 Receptor Agonist Shows Significant Improvements in Treatment of Metabolic Dysfunction-Associated Steatohepatitis in Phase II Trial
Survodutide produced a statistically significant improvement in metabolic dysfunction-associated steatohepatitis among 83% of those administered the drug compared to 18.2% of those given a placebo.
Bringing the Clinical Trials Industry Together
Micah Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and what attendees can expect at SCOPE.
Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial
Phase Ia, open-label, escalating dose study to evaluate the safety and immunogenicity of therapeutic vaccine, TherVacB.
Managing Digital Studies in the Current Landscape
Flo Mowlem, VP of Science at ObvioHealth discusses digital study design—touching on how to best manage data and medical devices.
FDA Issues Cautionary Reminder to Medical Device Manufacturers Regarding Data Submitted from Third-Party Laboratories
Agency reports concerns amid an increase in submitted data that has been fabricated, duplicated, or unreliable from third-party laboratories.
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial
Enrollment and initial follow up has been completed for study set to test efficacy of cancer vaccine in individuals with Lynch syndrome.
2 Commerce Drive Cranbury, NJ 08512